AbbVie announced that VRAYLAR is now listed as an exception medication status on the list of medications of the Regie de l’assurance maladie du Quebec for the treatment of schizophrenia. This announcement comes 12 months after the approval of VRAYLAR by Health Canada, bringing a new treatment option to Canadians living with schizophrenia.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
